Please use this identifier to cite or link to this item:
Title: Update on optimal management for pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.
Austin Authors: Nguyen, Mike ;Segelov, Eva;Goldstein, David;Pavlakis, Nick;Shapiro, Jeremy;Price, Timothy J;Nagrial, Adnan;Chantrill, Lorraine;Leong, Trevor;Chen, John;Burge, Matt;Karapetis, Christos S;Chau, Ian;Lordick, Florian;Renouf, Daniel;Tebbutt, Niall C ;Roy, Amitesh C
Affiliation: Medical Oncology
Department of Medical Oncology, School of Clinical Sciences, Monash University and Monash Health, Melbourne 3800, Australia
Department of Medical Oncology, Royal North Shore Hospital, University of Sydney, Sydney 2065, Australia
Cabrini Health, Monash University, Melbourne, Australia
The Queen Elizabeth Hospital/University of Adelaide, Adelaide, Australia
Division of Radiation Oncology, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Australia
Flinders Centre For Innovation in Cancer/ Flinders University, Bedford Park, South Australia, 5042, Australia
Dept. of Medical Oncology, Prince of Wales Hospital, University of NSW
Dept. of Medical Oncology, Westmead & Blacktown Hospitals. University of Sydney, NSW
Department Medical Oncology, Wollongong Hospital, Illawarra Shoalhaven Local Health District. NSW
Department of Cancer Care Services, Royal Brisbane Hospital, University of Queensland, Herston, Queensland
Dept. of Medicine, Royal Marsden Hospital, Institute of Cancer Research, Surrey, London, UK
University Cancer Center Leipzig and Department of Oncology, Gastroenterology, Hepatology, Pneumology and Infectious Diseases, Leipzig University Medical Center, Leipzig, Germany
Dept. of Medical Oncology, BC Cancer. Faculty of Medicine, University of British Columbia
Olivia Newton-John Cancer Wellness and Research Centre
Issue Date: 5-Nov-2021
Date: 2021-11-05
Publication information: Expert Review of Anticancer Therapy 2021; online first: 5 November
Abstract: Pancreatic cancer remains a challenging malignancy due to the high proportion of patients diagnosed at advanced stages and the limited treatment options. This article discusses recent evidence in the management of both localised and advanced pancreatic cancer and offers an expert opinion on current best practice. For patients with localised disease, the evidence for adjuvant chemotherapy is discussed as well as emerging neoadjuvant approaches for resectable, borderline resectable and locally advanced disease. Advances in metastatic disease are discussed including cytotoxic chemotherapy, targeted therapies and the role of genomic testing to identify patients with molecular alterations. Reviewed literature included; journal publications, abstracts presented at major international oncology meetings and ongoing clinical trials databases. Pancreatic cancer is a devastating diagnosis and despite recent advances has a very poor prognosis. Only a minority of patients, 20%, are diagnosed with potentially curable disease. The shifting paradigm towards neoadjuvant therapy may improve resectability and survival rates however robust evidence is required. Thus far, there has only been limited progress in advanced stage disease. Genomic testing may potentially identify more treatment targets although limited to small subgroups.
DOI: 10.1080/14737140.2022.2002689
ORCID: 0000-0002-3922-2693
Journal: Expert Review of Anticancer Therapy
PubMed URL: 34739362
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Sep 29, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.